Clinical Trials Browser

Brain Neoplasms, Neoplasms

Carcinoma, Squamous Cell

Biliary Tract Neoplasms

Carcinoma, Hepatocellular

Hematologic Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Endometrial Neoplasms

Carcinoma, Renal Cell

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

Vulvar Neoplasms

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular

Liver Neoplasms

Carcinoma, Renal Cell

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Biliary Tract Neoplasms, Cholangiocarcinoma

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Neoplasm Metastasis

Neuroendocrine Tumors

Thyroid Neoplasms

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Endometrial Neoplasms

Thyroid Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Metastatic Castration-Resistant Prostate Cancer

Carcinoma, Renal Cell

Carcinoma, Hepatocellular, Liver Neoplasms

Clinical Trials

Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases

Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment

Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer

SLIDE-HCC

MK-3475-587

KEYNOTE-B98

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer

SAMURAI

LaPemERLA

LONGIST

MITO VULVA-01

MK-6482-043

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Neoadjuvant Pembrolizumab and Lenvatinib for Renal Cell Carcinoma

MK-3475-06B

Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab

Keynote B59

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

HAIC-quad

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma

NeoLATC

Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer

KEYNOTE-365

Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC

MAGNATE-S

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma